A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

CompletadoFase 3ClinicalTrials.gov

ID: NCT02106390Tipo: INTERVENTIONALInicio: 5 de jun de 2014Fin estimado: 14 de oct de 2016

Traducción no disponible, mostrando original

Resumen

The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.

Elegibilidad

Edad mínima: 85 DaysEdad máxima: 119 DaysSexo: ALL

Criterios de inclusión

Healthy 3-month old infants (85-119 days, inclusive) at time of Visit 1 whose parents/legal guardians have given written informed consent after the nature of the study has been explained.
Available for all the visits scheduled in the study.
In good health as determined by medical history, physical examination and clinical judgment of the investigator.

Criterios de exclusión

History of any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) at the time of enrollment.
Previous known or suspected disease caused by N. meningitidis.
Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.
History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine.
Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from, for ex-ample:
Chronic administration of immunosuppressants or other immune-modifying drugs since birth (3 months prior). (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day or ≥ 10 mcg/day for children below 2 years. Inhaled and topical steroids are allowed),
Immune deficiency disorder, or known HIV infection.
Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation since birth.
History of any progressive or severe neurologic disorder, or seizure disorder or Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).
History of any bleeding disorder considered as a contraindication to intramuscular injection or blood draw.
Child's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
Receipt of any investigational or non-registered product since birth (3 month prior) or are expected to receive during the study period.
Family members or household members of site research staff.
Any clinically-significant chronic or progressive disease according to judgment of the investigator (pulmonary, cardiovascular, renal, hepatic or endocrine functional abnormality) or a congenital anomaly/known cytogenic disorder (e.g., Down's syndrome).
History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

Intervenciones

biological

Meningococcal group B Vaccine, rMenB+OMV NZ

4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

biological

Meningococcal ACWY Conjugate Vaccine, MenACWY

Ubicaciones

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Córdoba, Argentina

Patrocinadores

PrincipalGlaxoSmithKline

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3b, Open-Label, Randomized, Multicenter Study to ... | EligiMed